#132 Primary Robot Assisted Retroperitoneal LND in a Patient with Adenocarcinoma of Testis- Agrawal
This is one of the 2023 KS International Innovation Awards videos selected for inclusion in the Vattikuti Foundation – ORSI Humans on the Cutting Edge of Robotic Surgery Conference, October 6, 7 & 8, 2023 in Ghent, Belgium. Posting does not imply that is has been selected as a Finalist, just that the content will be discussed at the Conference.
From the entry: Dr. Mayank Agrawal
Title: Primary Robot Assisted Retroperitoneal Lymph Node Dissection in a Patient with Adenocarcinoma of Testis.
Introduction and Objectives: Adenocarcinoma as a primary malignancy in testis is very rare, especially the mucinous subtype. The exact incidence is unknown. The management options after high inguinal orchidectomy include retroperitoneal lymph node dissection (RPLND) and chemotherapy.
Materials and Methods: A 48-year-old man with a recent history of scrotal orchidectomy presented with a histopathology report suggestive of adenocarcinoma of the testis (mucinous type). Pre-operative serum tumor markers were normal. Staging FDG PET-CT was negative for abdominal lymphadenopathy but there was low-grade FDG uptake in the right scrotal sac. The management options for this uncommon testicular tumor were discussed with the institutional tumor board and with the patient. The patient underwent primary robot assisted RPLND and high inguinal scrotal exploration with excision of the scrotal skin scar.
Results: Surgery was performed using da Vinci Xi robotic system. The total console time was 3 hours and 20 minutes. The estimated intraoperative blood loss was 100 ml. There were no intra- operative or post-operative complications. The patient got discharged on post-operative day one. Final histopathology was suggestive of a poorly differentiated malignant tumor (likely seminoma) in one of the 42 lymph nodes that were harvested. Scrotal skin, right testicular remnant, and right spermatic cord were free of tumor. The patient received three cycles of etoposide and cisplatin-based chemotherapy post operatively. At 6 months follow up patient is free of any recurrence.
Conclusion: Rare histopathology like adenocarcinoma poses a treatment conundrum. Robot-assisted primary RPLND is a feasible management option with good surgical outcomes.